PENSACOLA, FL, November 20, 2025 – Ametris, a global digital health solutions provider transforming real-world patient data into validated clinical evidence, announced today a new partnership with Lingyan Innovation, a high-tech enterprise specializing in the digitalization of clinical research and development in China.
Ametris’ AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. This strategic partnership with Lingyan Innovation enables the deployment of medical-grade wearable digital health technology within decentralized clinical trials in China, bringing global standards for data quality and regulatory compliance to one of the world’s fastest-growing research environments.
Lingyan Innovation offers a Decentralized Clinical Trial (DCT) technical platform and supporting digital operation services to support patient-centered and compliance-first clinical trials. They have developed the fully integrated Lingyan Clinical Trial Management Platform, Lingyan (physician end) and Yanxin (patient end), as well as the Lingyan RBQM Quality Management Visualization Platform, to carry out end-to-end process operation and quality management, achieving cost reduction and efficiency improvements.
"This collaboration represents a meaningful step toward globalizing the use of high-quality digital health data in clinical development,” said Christine Guo, Chief Scientific Officer at Ametris. “By combining Ametris’ validated wearable technology and scientific expertise with Lingyan Innovation's advanced digital trial platform and operational services, we can support Chinese researchers and global sponsors in running more efficient, patient-centric studies.”
“Partnering with Ametris strengthens our mission to advance the digitalization of clinical research in China,” said Gaoyang LI, Founder & Chief Executive Officer, at Lingyan Innovation. “Together, we’re enabling sponsors to integrate medical-grade wearable data into decentralized trials to enhance data quality, improve patient engagement, and accelerate the path to innovation. I believe the partnership between Ametris and Lingyan Innovation will simplify investigator-initiated and sponsor-initiated trials.”
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
About Lingyan Innovation
Lingyan Innovation Health Technology is a leading full-process digital platform and digital operation provider in China, focusing on the digitalization and intelligence of clinical research and development. Aiming to establish a new paradigm for digital operation and quality management in clinical trials, our advanced Decentralized Clinical Trial (DCT) and Risk Based Quality Management (RBQM) solutions widely recognized by regular agency, investigators, and sponsors.
